DOV Pharmaceutical
From Wikipedia, the free encyclopedia
DOV Pharmaceutical, a biotechnology company, focuses on therapies primarily for central nervous system conditions. The firm's lead drug candidate, Indiplon, is said to treat insomnia. Indiplon targets the same subset of neurotransmitter receptors affected by Valium and Xanax, but with more specificity to avoid the side effects associated with those drugs. DOV Pharmaceutical, Neurocrine Biosciences, and Pfizer are working on the candidate. Other candidates in DOV's pipeline target depression and angina, pain, anxiety, high blood pressure, and other disorders.
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
